Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Institutes of Health (CA198999)
- License Information
-
More Information
Article History
Received: 7 January 2021
Accepted: 16 February 2021
First Online: 25 February 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: LH is a consultant for PDS Biotechnology, Samyang Biopharmaceuticals, and Stemirna Therapeutics. LM is currently a full time employee of Gilead and this article is not related to the underlying work at Gilead and it is with the approval of Gilead. No potential conflict of interest exists.
